Star Health & Allied Insurance Upgraded to Hold on Technical Improvements and Mixed Fundamentals

Quality Assessment: Strong Fundamentals Amidst Flat Quarterly Performance

Star Health & Allied Insurance continues to demonstrate robust long-term fundamental strength, with a compound annual growth rate (CAGR) of 19.27% in operating profits. This growth trajectory underpins the company’s ability to generate consistent earnings over time, a key factor in its quality rating. However, the recent quarter (Q3 FY25-26) showed flat financial performance, signalling some near-term challenges. The company’s net profit after tax (PAT) for the first nine months stood at ₹445.64 crores, reflecting a decline of 30.95% compared to the previous period. This contraction in profitability tempers the otherwise strong fundamentals and warrants cautious optimism.

Institutional investors hold a significant 35.03% stake in the company, indicating confidence from well-resourced market participants who typically conduct thorough fundamental analysis. This institutional backing adds credibility to the company’s quality profile despite recent earnings softness.

Valuation: Premium Pricing Amidst Modest Returns

Star Health’s valuation remains on the expensive side, trading at a price-to-book (P/B) ratio of 3.6, which is notably higher than the average historical valuations of its peers in the insurance sector. This premium valuation is supported by the company’s market-beating stock performance, with a 26.34% return over the past year, significantly outperforming the BSE500 index’s 0.76% gain during the same period.

However, this strong share price appreciation contrasts with the company’s underlying earnings trend, which has deteriorated with profits falling by 43.4% over the last year. The return on equity (ROE) stands at a modest 6%, suggesting that the company’s profitability relative to shareholder equity is limited. Investors should weigh the premium valuation against these mixed financial signals when considering the stock’s attractiveness.

Financial Trend: Mixed Signals with Flat Sales and Declining Profits

The company’s financial trend presents a complex picture. While operating profits have grown at a healthy CAGR of 19.27%, net sales have declined sharply at an annual rate of -50.00%, indicating challenges in top-line growth. This decline in sales is a significant concern, as it suggests pressure on the company’s ability to expand its revenue base.

Profit after tax has also contracted by nearly 31% over the nine-month period, reflecting margin pressures or increased costs. Despite these setbacks, the company’s stock has outperformed the broader market indices, highlighting a disconnect between market sentiment and fundamental earnings trends.

Technical Analysis: Shift to Mildly Bullish Momentum

The upgrade in Star Health’s investment rating is largely attributable to improvements in its technical indicators. The technical trend has shifted from mildly bearish to mildly bullish, signalling a positive change in market momentum. Key technical metrics reveal a mixed but improving outlook:

• MACD on a weekly basis is bullish, although monthly readings remain mildly bearish.
• Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts, indicating a neutral momentum.
• Bollinger Bands remain bearish on weekly and monthly timeframes, suggesting some volatility and potential resistance.
• Daily moving averages have turned mildly bullish, supporting short-term upward price movement.
• KST indicator is bearish weekly but mildly bullish monthly, reflecting a gradual improvement in trend strength.
• Dow Theory assessments are mildly bullish on both weekly and monthly charts, reinforcing the positive technical shift.
• On-Balance Volume (OBV) shows no clear trend, indicating volume is not strongly confirming price moves.

These technical improvements have contributed to the MarketsMOJO Mojo Score rising to 51.0, with the Mojo Grade upgraded from Sell to Hold as of 20 March 2026. The stock’s current price stands at ₹453.30, marginally up 0.10% from the previous close of ₹452.85, trading well above its 52-week low of ₹330.05 but below the 52-week high of ₹533.90.

Comparative Market Performance

Star Health’s stock returns have outpaced the Sensex and broader market indices over the past year, delivering a 26.34% gain compared to the Sensex’s -2.38% return. However, over longer periods such as three years, the stock has underperformed with a -16.61% return versus the Sensex’s 29.33% gain. This mixed performance underscores the importance of monitoring both short-term momentum and long-term fundamentals when evaluating the stock.

Investment Outlook and Considerations

Star Health & Allied Insurance’s upgrade to a Hold rating reflects a balanced view of its prospects. The company’s strong operating profit growth and institutional backing provide a solid foundation, while the recent technical improvements suggest potential for further price appreciation in the near term. Nevertheless, investors should remain cautious given the flat quarterly results, declining net sales, and expensive valuation metrics.

With a modest ROE of 6% and a P/B ratio of 3.6, the stock trades at a premium that may not be fully justified by current earnings trends. The divergence between strong share price returns and weakening profitability highlights the need for careful monitoring of upcoming financial results and market developments.

Overall, the Hold rating signals that while Star Health is no longer a sell, it may not yet be a compelling buy until clearer signs of sustained earnings recovery and valuation support emerge. Investors seeking exposure to the insurance sector should weigh these factors alongside broader market conditions and alternative opportunities.

Summary of Rating Change

The upgrade from Sell to Hold on 20 March 2026 was driven primarily by:

• Technical Trend: Shift from mildly bearish to mildly bullish, supported by positive MACD weekly readings and improving moving averages.
• Quality: Strong long-term operating profit growth (19.27% CAGR) and high institutional ownership (35.03%).
• Financial Trend: Mixed signals with flat quarterly results and declining net sales, but resilient stock performance.
• Valuation: Expensive at 3.6 P/B ratio, justified partially by market-beating returns but tempered by low ROE and profit declines.

These factors combined to raise the MarketsMOJO Mojo Score to 51.0 and improve the Mojo Grade to Hold, reflecting a more balanced risk-reward profile for investors.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today